- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 风雨不动 于 2012-4-14 16:00 编辑
From the analyst's couch: Hepatitis C - pipeline update
February, 2011
Nature Reviews Drug Discovery
Over 3% of the world's population is chronically infected with hepatitis C virus (HCV). Chronic hepatitis C (CHC) is a major cause of liver damage, cirrhosis and liver cancer that can lead to liver failure and death. The current standard of care (SOC) is a combination of pegylated interferon with ribavirin (PEG-IFN/RBV), but this only eradicates the virus in approximately 50% of patients.
The recently concluded sixty-first annual meeting of the American Association for the Study of Liver Diseases (AASLD) provided a broad overview of the pipeline of novel drugs for the treatment of CHC. It is clear that this field is on the brink of significant improvements to the SOC that should follow the highly anticipated approval of the first direct antiviral agents (DAAs), telaprevir (Vertex/Johnson & Johnson/Mitsubishi) and boceprevir (Merck), in 2011.
Read the full story here
http://www.nature.com/nrd/journal/v10/n2/full/nrd3361.html
超过3%的世界人口是慢性感染了丙型肝炎病毒(HCV)。慢性丙型肝炎(文委会)是肝损伤,肝硬化和肝癌,可导致肝功能衰竭和死亡的主要原因。对护理(SOC)的现行标准是与利巴韦林(PEG-IFN/RBV)聚乙二醇化干扰素的组合,但是这是在大约50%的患者病毒只根除。
最近结束的第六十一届美国协会年度会议,为肝脏疾病(美国肝病学会)的研究提供了一种新型的药物治疗管道的文委会全面概述。很显然,这个领域的重大改进边缘的有机碳,应遵循的第一个直接抗病毒药物备受瞩目的批准(DAAs),telaprevir(顶点/强生公司/三菱)和boceprevir(默克公司),在被2011年。
阅读完整的故事在这里
http://www.nature.com/nrd/journal/v10/n2/full/nrd3361.html
(6.合.彩)足球.篮球...各类投注开户下注
第一投注现金网:招代理年薪10万以上:yyu.cc |
|